TB Vaccine Safe in Persons with Latent Disease

The MVA85A vaccine was safe and induced specific in vitro responses in individuals with latent TB.

TB currently infects one third of the world’s population, and infected immunocompetent individuals have a 5% to 10% chance of developing active disease. A vaccine that is more immunogenic than BCG could substantially reduce TB incidence worldwide, but it must be safe in persons with latent infection.

In a study involving 12 volunteers with evidence of latent TB infection (LTBI), researchers in the U.K. evaluated the safety and efficacy of a new TB vaccine, MVA85A (modified vaccinia Ankara expressing antigen 85A). All participants demonstrated reactivity to Mycobacterium tuberculosis–specific antigens on an interferon-γ (IFN-γ) ELISpot assay.

Local or systemic adverse events were comparable between participants with LTBI and volunteers without…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

TB Vaccine Safe in Persons with Latent Disease

Topics

Reviewing Author